Search results for "g factor"

showing 10 items of 514 documents

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct

A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor i…

1994

Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days. In the phase I part of the study, groups of 3 patients received EDXR 20, 25, 30, 35, and 40 mg/m2/day until the dose limiting toxicity (DLT) was reached. At the dose of 40mg/m2/day prolonged grade 4 leukopenia, severe proctitis, and grade 3 diarrhea represented the DLT. All subsequent partients were treated at the maximal tolerated dose of EDXR (35 mg/m2/day). In the group of 18 patients treated at 3…

medicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia Medicamedicine.medical_treatmentLeucovorinBreast NeoplasmsGastroenterologyDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineCarcinomaHumansRadiology Nuclear Medicine and imagingCyclophosphamideEpirubicinChemotherapyLeukopeniabusiness.industryCarcinomaHematologyGeneral MedicineLeukopeniaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryGranulocyte colony-stimulating factorSettore MED/18 - Chirurgia GeneraleRegimenTreatment OutcomeOncologyFluorouracilToxicityFemaleFluorouracilmedicine.symptombusinessmedicine.drugActa oncologica (Stockholm, Sweden)
researchProduct

PHP39 Explaning Differences in EU5 Market Penetration Levels and Rates of Biosimilars: The Case of Epoetine, Granulocyte-Colony Stimulating Factor, a…

2012

medicine.medical_specialtyEndocrinologyInternal medicineHealth PolicymedicinePublic Health Environmental and Occupational HealthBiosimilarBiologyGrowth hormoneGranulocyte colony-stimulating factorMarket penetrationValue in Health
researchProduct

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

2019

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhib…

medicine.medical_specialtyFactor concentrate610 Medicine & healthReview Article030204 cardiovascular system & hematologyHemophilia ADrug SubstitutionHemophilia BFactor IX03 medical and health sciencesDrug substitution0302 clinical medicinePharmacokineticsmedicineDosingIntensive care medicineFactor IXClotting factorOriginal Articles: Haemostasisfactor IXFactor VIIIlcsh:RC633-647.5business.industryDosing regimenlcsh:Diseases of the blood and blood-forming organsHematology3. Good healthOnline‐only Articlesfactor VIII3121 General medicine internal medicine and other clinical medicinedrug substitution10032 Clinic for Oncology and Hematologydrug substitution; factor IX; factor VIII; hemophilia A; hemophilia Bhemophilia Bhemophilia Abusiness030215 immunologymedicine.drug
researchProduct

Pentobarbital-sensitive EDHF comediates ACh-induced arteriolar dilation in the hamster microcirculation

1999

It is unclear to what extent the endothelium-derived hyperpolarizing factor (EDHF) contributes to the control of microcirculatory blood flow in vivo. We analyzed, by intravital microscopy in hamster muscles, the potential role of EDHF along the vascular tree under stimulated (ACh) or basal conditions. Experiments were performed in conscious as well as anesthetized (pentobarbital, urethan) animals. Additionally, cellular effects of the potential EDHF were studied in isolated small arteries. In pentobarbital-anesthetized animals, treatment with N ω-nitro-l-arginine (l-NNA; 30 μmol/l) and indomethacin (3 μmol/l) reduced the dilation in response to 10 μmol/l ACh from 60 ± 6 to 20 ± 4%. This ni…

medicine.medical_specialtyPentobarbitalEndothelium-derived hyperpolarizing factorPotassium ChannelsCharybdotoxinPhysiologyVasodilator AgentsIndomethacinHamsterVasodilationNitroarginineMuscle Smooth VascularMicrocirculationGlibenclamideBiological FactorsCytochrome P-450 Enzyme SystemArterioleCricetinaePhysiology (medical)Internal medicinemedicine.arterymedicineAnimalsCyclooxygenase InhibitorsMuscle SkeletalPentobarbitalSkinMesocricetusChemistryMicrocirculationPenicillamineAcetylcholineArteriolesEndocrinologyAnesthesiaFatty Acids UnsaturatedPotassiumEndothelium VascularCardiology and Cardiovascular MedicineIntravital microscopyAdjuvants Anesthesiamedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs.

1993

Abstract Rolipram (0·1–1000 μg kg−1, i.v.) reduced the increase in microvascular permeability induced by platelet-activating factor (PAF; 50 ng kg−1, i.v.) at different sites of the guinea-pig airways. Rolipram (1–100μg kg−1, i.v.) inhibited histamine (30μg kg−1, i.v.)-and bradykinin (0·3 μg kg, i.v.)-induced airway microvascular leakage. These effects of rolipram were obtained at doses which inhibit histamine (7–20 μg kg−1 min−1)-induced bronchoconstriction (IC50 = 3 ± 1 μg kg, i.v.) without depressing arterial blood pressure in the guinea-pig. Aminophylline (50 mg kg−1) did not change the effect of PAF. The anti-exudative effect of rolipram is of potential therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsGuinea PigsPharmaceutical ScienceBradykininVascular permeabilityBlood PressureBronchiBradykininCapillary Permeabilitychemistry.chemical_compoundInternal medicinemedicineAnimalsDrug InteractionsPlatelet Activating FactorRolipramPharmacologyPlatelet-activating factorMicrocirculationAminophyllinePyrrolidinonesTracheaEndocrinologymedicine.anatomical_structurechemistryBronchoconstrictionAminophyllinemedicine.symptomRolipramHistaminemedicine.drugBlood vesselEvans BlueHistamineThe Journal of pharmacy and pharmacology
researchProduct

ROLIPRAM INHIBITS PAF-INDUCED AIRWAY MICROVASCULAR LEAKAGE IN GUINEA-PIG - A COMPARISON WITH MILRINONE AND THEOPHYLLINE

1992

The effects of 3 phosphodiesterase (PDE) inhibitors, rolipram (PDE IV), milrinone (PDE III) and theophylline (non-selective) on PAF (50 ng kg-1; iv)-induced airway vascular leakage have been evaluated in guinea-pigs. Rolipram (3-300 micrograms kg-1; iv) reduced the increase in permeability induced by PAF at all airway levels whereas milrinone (10-1000 micrograms kg-1; iv) and theophylline (30 mg kg-1; iv) were without effects. The anti-leakage activity of rolipram may be of therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsPyridonesGuinea PigsRespiratory SystemVascular permeabilityCapillary Permeabilitychemistry.chemical_compoundTheophyllineInternal medicinemedicineAnimalsPharmacology (medical)TheophyllinePlatelet Activating FactorRolipramPharmacologybiologyCyclic nucleotide phosphodiesterasePlatelet-activating factorbusiness.industryPhosphodiesterasePyrrolidinonesEndocrinologychemistryEnzyme inhibitorbiology.proteinMilrinonebusinessRolipramEvans BlueMilrinonemedicine.drug
researchProduct

Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multic…

2011

Granulocyte colony-stimulating factor (G-CSF) induces a transient mobilization of hematopoietic progenitor cells from bone marrow to peripheral blood. Our aim was to evaluate safety of repeated courses of G-CSF in patients with amyotrophic lateral sclerosis (ALS), assessing disease progression and changes in chemokine and cytokine levels in serum and cerebrospinal fluid (CSF). Twenty-four ALS patients entered an open-label, multicenter trial in which four courses of G-CSF and mannitol were administered at 3-month intervals. Levels of G-CSF were increased after treatment in the serum and CSF. Few and transitory adverse events were observed. No significant reduction of the mean monthly decrea…

medicine.medical_specialtyPhysiologybusiness.industryMonocyteGranulocytemedicine.diseaseGastroenterologyGranulocyte colony-stimulating factorProinflammatory cytokineCellular and Molecular Neurosciencemedicine.anatomical_structureCerebrospinal fluidPhysiology (medical)Internal medicineMulticenter trialImmunologymedicineNeurology (clinical)Bone marrowAmyotrophic lateral sclerosisbusinessMuscle & Nerve
researchProduct

Endothelial modulation of 5-hydroxytryptamine-induced contraction in goat cerebral arteries.

1993

Abstract 1. 1. In isolated goat middle cerebral artery segments, 5-hydroxytryptamine (5-HT, 10 −8 −3 × 10 −5 M) caused concentration-dependent contractions, with EC 50 = 2.1 (1.9−2.5) × 10 −7 M and E max = 60 ± 2% of 50 mM KCl-induced contraction. 2. 2. Mechanical removal of endothelium significantly increased the E max (91 ± 8%) and did not change the EC 50 value of 5-HT-elicited contractions. 3. 3. Incubation of unrubbed arteries with the irreversible inhibitor of EDRF, gossypol (10 −5 M), significantly increased the contractile response to 5-HT ( E max = 77 ± 4%). 4. 4. Incubation of unrubbed arteries with the competitive inhibitor of the NO synthesis, N G -nitro - l -arginine (L-NOARG) …

medicine.medical_specialtySerotoninContraction (grammar)ArginineEndotheliumCerebral arteriesIndomethacinProstacyclinIn Vitro TechniquesArginineNitric OxideNitroarginineMuscle Smooth Vascularchemistry.chemical_compoundInternal medicinemedicine.arteryIsometric ContractionmedicineAnimalsPharmacologyChemistryGoatsEndothelium-derived relaxing factorGossypolAnatomyCerebral ArteriesEpoprostenolEndocrinologymedicine.anatomical_structureMiddle cerebral arteryFemaleEndothelium Vascularmedicine.symptomVasoconstrictionmedicine.drugMuscle ContractionGeneral pharmacology
researchProduct

Diastolic dysfunction and central obesity related hypertension: role of trasforming growth factor beta-1

2004

Abstract P-368 Key Words: Diastolic Dysfunction, Obesity Related Hypertension, Trasforming Growth Factor beta-1

medicine.medical_specialtySettore MED/09 - Medicina InternaMegalencephalic leukoencephalopathy with subcortical cystsmedicine.medical_treatmentDiastoleSettore MED/10 - Malattie Dell'Apparato RespiratorioOverweightLeft ventricular hypertrophyInternal medicineInternal MedicinemedicineSystolebiologybusiness.industryGrowth factorDiastolic Dysfunction Obesity Related Hypertension Trasforming Growth Factor beta-1Transforming growth factor betaDiastolic dysfunction HypertensionTrasforming factor beta 1medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityEndocrinologybiology.proteinCardiologymedicine.symptombusinessAmerican Journal of Hypertension
researchProduct